Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Nanosynex

Financiado

Cerrado

Ultra fast Antimicrobial Susceptibility Test for diagnosing antimicrobial resist...

Ultra fast Antimicrobial Susceptibility Test for diagnosing antimicrobial resistance to provide personalized antibiotic treatments Antimicrobial Resistance (AMR), is the ability of microorganisms to resist to antibiotics treatment, contributes to 700,000 deaths a year (25,000 deaths in Europe). Besides, The financial implications of AMR proliferation are deva... ver más

30/09/2024

Nanosynex

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

NANOSYNEX LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-09-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

Nanosynex

2.56M€ | Lider

HORMINOR HISPANIA

194.68K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BE FAST Bacterial Eavesdropping for Fast Antibiotic Susceptibility T... 2M€ Cerrado

TED2021-132122B-C22 DISEÑO Y SINTESIS DE NANODISPOSITIVOS BIOMOLECULARES SOSTENI... 151K€ Cerrado

Nanosynex Ultra fast Antimicrobial Susceptibility Test for diagnosing... 71K€ Cerrado

BacterOMIC Intelligence for precision therapies against antimicrobial r... 3M€ Cerrado

GRAPHFITI Graphene to Fight Antimicrobial Resistance 150K€ Cerrado

PID2020-114347RB-C32 DISEÑO, SINTESIS, PROPIEDADES FOTOFISICAS Y ACTIVIDAD ANTIMI... 125K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2020-09-21
Fecha Fin: 2024-09-30

Líder del proyecto

NANOSYNEX LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Antimicrobial Resistance (AMR), is the ability of microorganisms to resist to antibiotics treatment, contributes to 700,000 deaths a year (25,000 deaths in Europe). Besides, The financial implications of AMR proliferation are devastating for the global healthcare system. The current implementation of antimicrobial stewardship programs in hospitals has not been enough to mitigate the overuse and misuse of antibiotics. Current AST (Antimicrobial Susceptibility Testing) diagnostic methods are highly accurate but take too long (a few days) forcing doctors in many case to prescribe non-personalised treatments. The overuse and misuse of antibiotics, due to the lack of efficient solutions to detect bacterial resistance at an early stage, allows the emergence of superbugs and the spread of the resistant bacteria in the environment resulting in more infected patients and increasing the major global threat of Antimicrobial Resistance (AMR). Nanosynex product provides a revolutionary, low-cost, ultra-fast AST (Antimicrobial Susceptibility Testing) technology that delivers results in an average of only 4 hours in average, and as little as 2 hours for certain bacteria type. Nanosynex will allow physicians to get same-day AST results and to prescribe personalised and effective antibiotic treatment, with a unique test that will save at least one day of hospitalization per patient, as well as avoid pandemics outbreaks such as the current case of COVID-19. Consequently, Nanosynex will contribute to reduce the spread of resistant bacteria and significantly reduce the large economic burden associated with antimicrobial resistance. This EIC project aims the industrialization and scalability of Nanosynex benchtop and cards, performing the clinical trials to get the CE mark for its commercialisation across the EU. Nanosynex expects to reach a positive cash flow generation by the end of 2026 in the targeted scenario, with sales of +€27.5M.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores